Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
15.79
+0.02 (0.13%)
Aug 20, 2025, 4:00 PM - Market closed

Company Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis.

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.

Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics logo
CountryUnited States
Founded2016
IPO DateJan 31, 2020
IndustryBiotechnology
SectorHealthcare
Employees342
CEOTodd Watanabe

Contact Details

Address:
3027 Townsgate Road, Suite 300
Westlake Village, California 91361
United States
Phone805 418 5006
Websitearcutis.com

Stock Details

Ticker SymbolARQT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001787306
CUSIP Number03969K108
ISIN NumberUS03969K1088
Employer ID81-2974255
SIC Code2834

Key Executives

NamePosition
Todd Franklin Watanabe M.A.President, Chief Executive Officer and Director
Dr. Bhaskar Chaudhuri Ph.D.Co-Founder and Independent Director
Masaru Matsuda Esq., J.D.Senior Vice President, General Counsel and Corporate Secretary
Dr. Patrick E. Burnett M.D., Ph.D.Executive Vice President and Chief Medical Officer
Larry Todd EdwardsExecutive Vice President and Chief Commercial Officer
Latha VairavanChief Financial Officer
Rajvir MadanChief Digital and Technology Officer
Amanda SheldonHead of Corporate Communications
Kent TaylorSenior Vice President of Sales
Aleen HosdaghianVice President of Marketing

Latest SEC Filings

DateTypeTitle
Aug 20, 2025SCHEDULE 13D/AFiling
Aug 19, 2025144Filing
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 8, 2025144Filing
Aug 8, 2025144Filing
Aug 6, 202510-QQuarterly Report
Aug 6, 20258-KCurrent Report
Aug 6, 2025144Filing
Aug 4, 2025144Filing
Aug 4, 2025144Filing